Nucleo Tech
1 known investors
Find your way into Nucleo Tech
256 people in our graph share verified history with the Nucleo Tech team — schools, employers, funds. One of them is your warm intro.
Logan Hilleunlockedknows Shachar Dagan · together at Harvard Medical School (overlapped)
×8knows the team · via Harvard Medical School
×3knows the team · via Howard Hughes Medical Institute
NucleoTech engineers BrainPortal carrier proteins that attach to therapeutic antibodies and oligonucleotides and transport them across the blood-brain barrier non-invasively, using a direct in vivo screening platform to test many candidates simultaneously. It advances internal CNS therapeutics and licenses its carriers to pharma and biotech partners.
Founders & leadership
UB
Uriah BekensteininCo-Founder & CEOUriah Bekenstein holds a Ph.D. in molecular neurobiology under Prof. Hermona Soreq and an M.Sc. under S. Kadener, with research focused on neurodegenerative conditions using molecular biology and biochemistry; he is a USPTO patent agent and Co-Founder & CEO of NucleoTech.
NC
Naftali CohenCo-Founder & CBO
AK
Adi KoplovitzinCo-Founder & COOAdi Koplovitz is Co-Founder and COO of NucleoTech, which develops carrier proteins to transport therapeutics across the blood-brain barrier. He has background in strategy, market analysis, and financial modeling.
SD
Shachar DaganinHead of ResearchShachar Dagan is a neuroscientist with 15 years of research experience in molecular neurobiology, viral vector development, and animal models. He brings expertise in genetic regulation of CNS cells, in vivo genetic engineering, and blood-brain barrier biology to his role as Head of Research at NucleoTech.
Investors · 1
Competitors · 1
by search overlap
Companies competing with Nucleo Tech for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Nucleo Tech do?
- NucleoTech engineers BrainPortal carrier proteins that attach to therapeutic antibodies and oligonucleotides and transport them across the blood-brain barrier non-invasively, using a direct in vivo screening platform to test many candidates simultaneously. It advances internal CNS therapeutics and licenses its carriers to pharma and biotech partners.
- Who founded Nucleo Tech?
- Nucleo Tech was founded by Uriah Bekenstein, Naftali Cohen, Adi Koplovitz.
- Who are Nucleo Tech's investors?
- Nucleo Tech's investors include The Innovation Space.